20-F/A
Annual Report (Foreign)
Cordyceps Sunshine Biotech Holdings Co., Ltd. RAJAF
0001213900-25-090714
- Filed
- Sep 23, 2025 12:00 AM ET
- Period of report
- —
Amendment.
Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Shares Diluted | FY 2023 · Dec 31, 2023 | 111.12M sh |
| Shares Diluted | FY 2023 · Dec 31, 2022 | 104.42M sh |
| Shares Diluted restated | FY 2023 · Dec 31, 2021 | 100K sh |
| Shares Outstanding | FY 2023 · Dec 31, 2023 | 111.12M sh |
| Capex restated | FY 2023 · Dec 31, 2023 | $319.49K |
| Capex restated | FY 2023 · Dec 31, 2021 | $100K |
| Operating Cash Flow restated | FY 2023 · Dec 31, 2023 | $359.72K |
| Operating Cash Flow | FY 2023 · Dec 31, 2022 | −$321.38K |
| Operating Cash Flow | FY 2023 · Dec 31, 2021 | −$365.36K |
| Long Term Debt | FY 2023 · Dec 31, 2023 | $431.08K |
| Long Term Debt | FY 2023 · Dec 31, 2022 | $414K |
| Cash And Equivalents restated | FY 2023 · Dec 31, 2023 | $23.1K |
| Cash And Equivalents restated | FY 2023 · Dec 31, 2022 | $6.63K |
| Stockholders Equity restated | FY 2023 · Dec 31, 2023 | −$151.8K |
| Stockholders Equity | FY 2023 · Dec 31, 2022 | −$951.33K |
| Stockholders Equity | FY 2023 · Dec 31, 2021 | −$275.81K |
| Stockholders Equity | FY 2023 · Dec 31, 2020 | −$12.81K |
| Current Liabilities restated | FY 2023 · Dec 31, 2023 | $2.97M |
| Current Liabilities restated | FY 2023 · Dec 31, 2022 | $2.52M |
| Total Liabilities restated | FY 2023 · Dec 31, 2023 | $3.5M |
| Total Liabilities | FY 2023 · Dec 31, 2022 | $3.06M |
| Current Assets restated | FY 2023 · Dec 31, 2023 | $327.18K |
| Current Assets | FY 2023 · Dec 31, 2022 | $501.55K |
| Total Assets restated | FY 2023 · Dec 31, 2023 | $3.35M |
| Total Assets | FY 2023 · Dec 31, 2022 | $2.1M |
| Eps Diluted | FY 2023 · Dec 31, 2023 | $0.01 |
| Eps Diluted | FY 2023 · Dec 31, 2022 | −$0.01 |
| Eps Diluted restated | FY 2023 · Dec 31, 2021 | −$4.91 |
| Eps Basic | FY 2023 · Dec 31, 2023 | $0.01 |
| Eps Basic | FY 2023 · Dec 31, 2022 | −$0.01 |
| Eps Basic restated | FY 2023 · Dec 31, 2021 | −$4.91 |
| Sga Expense | FY 2023 · Dec 31, 2023 | $538.55K |
| Sga Expense restated | FY 2023 · Dec 31, 2022 | $336.24K |
| Sga Expense restated | FY 2023 · Dec 31, 2021 | $94.34K |
| Net Income restated | FY 2023 · Dec 31, 2023 | $751.61K |
| Net Income | FY 2023 · Dec 31, 2022 | −$720.09K |
| Net Income | FY 2023 · Dec 31, 2021 | −$491.01K |
| Operating Income restated | FY 2023 · Dec 31, 2023 | $227.83K |
| Operating Income restated | FY 2023 · Dec 31, 2022 | −$415.12K |
| Operating Income restated | FY 2023 · Dec 31, 2021 | −$119.39K |
| Gross Profit | FY 2023 · Dec 31, 2023 | $766.39K |
| Gross Profit restated | FY 2023 · Dec 31, 2022 | $39.56K |
| Cost Of Revenue | FY 2023 · Dec 31, 2023 | $116.15K |
| Cost Of Revenue restated | FY 2023 · Dec 31, 2022 | $13.75K |
| Revenue | FY 2023 · Dec 31, 2023 | $882.53K |
| Revenue restated | FY 2023 · Dec 31, 2022 | $53.3K |
| Rd Expense | FY 2023 · Dec 31, 2022 | $118.44K |
| Rd Expense | FY 2023 · Dec 31, 2021 | $25.05K |